Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis-Reference-Cited by-同舟云学术

Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis

Published:2018-03-20 Issue:2 Volume:25 Page:513-520
ISSN:1219-4956
Container-title:Pathology & Oncology Research
language:en
Short-container-title:Pathol. Oncol. Res.

Author:

Inno Alessandro^ORCID,Di Noia Vincenzo,Martini Maurizio,D’Argento Ettore,Di Salvatore Mariantonietta,Arena Vincenzo,Schinzari Giovanni,Orlandi Armando,Larocca Luigi Maria,Cassano Alessandra,Barone Carlo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12253-018-0404-x.pdf

Reference34 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. https://doi.org/10.3322/caac.20107

2. Minuti G, D'Incecco A, Cappuzzo F (2013) Targeted therapy for NSCLC with driver mutations. Expert Opin Biol Ther 13:1401–1412. https://doi.org/10.1517/14712598.2013.827657

3. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med 375:1823–1833. https://doi.org/10.1056/NEJMoa1606774

4. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627

5. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced Nonsquamous non-small-cell lung Cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro evidence for the potential of EGFR inhibitors to decrease the TGF-β1-induced dispersal of circulating tumour cell clusters mediated by EGFR overexpression;Scientific Reports;2024-08-28

2. Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications;MedComm;2023-05-02

3. Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer;European Journal of Cancer;2022-01

4. Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer;Biochemical Pharmacology;2021-07

5. Synthesis and evaluation of new 4(3H)-Quinazolinone derivatives as potential anticancer agents;Journal of Molecular Structure;2020-01